Allowance to extend into 2036 patent claims related to method of treating patients with A-T using the company’s proprietary EryDex process Charles Ryan, J.D., Ph.D., Quince’s President and ...

You've experienced symptoms of a medical problem, visited one or more healthcare providers, and have undergone medical tests. Now, your healthcare provider will use all that evidence to arrive at your ...

COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. People with COPD often have trouble ...

This PrimeView highlights the pathophysiology of chronic kidney disease and summarizes the epidemiology, diagnosis and management of this disease. It accompanies the Primer article on this topic ...

It consists of episodes during which the symptoms last for at least two weeks. Depression can last for several weeks, months, or years. For many people, it is a chronic illness that gets better ...

announced the online publication of safety data from patients with Ataxia-Telangiectasia (A-T) treated with EryDex for a minimum of 24 months in Frontiers in Neurology. "A-T is a rare pediatric ...

“We have the first device to treat macular telangiectasia type 2, which has been through the clinical trial program, and the long-term results up to 9 years find that it is still relatively well ...

However, dyspnea usually relates to health problems. Sometimes, it is just a case of inactivity, and exercise can improve symptoms. However, dyspnea can be a sign of a serious health issue.

BACKGROUND: To our knowledge, there have been no reports on the control of central nervous system symptoms in patients with ataxia-telangiectasia. OBJECTIVE: To preliminarily determine the ...